Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BELFB
2676
Bel Fuse Inc Class B
BELFB
$4.25B
| $2.75M | ﹤0.01% |
16,198
+232
| +1% | +$36.3K |
|
2677
Lindblad Expeditions
LIND
$2.24B
| $2.73M | ﹤0.01% |
189,582
+7,183
| +4% | +$90.6K |
|
2678
PUT
General Motors
GM
$75.8B
| $2.73M | ﹤0.01% |
33,600
+25,000
| +291% | +$1.76M |
|
2679
Vanguard FTSE Developed Markets ETF
VEA
$239B
| $2.73M | ﹤0.01% |
43,712
-1,024
| -2% | -$62.7K |
|
|
DAWN
2680
DELISTED
Day One Biopharmaceuticals
DAWN
| $2.72M | ﹤0.01% |
292,325
-54,860
| -16% | -$458K |
|
2681
Stepan Co
SCL
$1.48B
| $2.72M | ﹤0.01% |
57,515
+6,579
| +13% | +$301K |
|
2682
Goosehead Insurance
GSHD
$2.33B
| $2.72M | ﹤0.01% |
36,972
+2,900
| +9% | +$207K |
|
2683
National Healthcare
NHC
$3.47B
| $2.72M | ﹤0.01% |
19,805
+1,820
| +10% | +$235K |
|
2684
ASP Isotopes
ASPI
$539M
| $2.71M | ﹤0.01% |
506,788
+274,424
| +118% | +$2.18M |
|
2685
REX American Resources
REX
$1.44B
| $2.7M | ﹤0.01% |
83,598
+493
| +0.6% | +$16.1K |
|
2686
Independent Bank Corp
IBCP
$854M
| $2.7M | ﹤0.01% |
82,959
+8,406
| +11% | +$270K |
|
2687
PACS Group
PACS
$7.2B
| $2.69M | ﹤0.01% |
70,102
+5,595
| +9% | +$123K |
|
2688
MSC Industrial Direct
MSM
$6.67B
| $2.68M | ﹤0.01% |
31,905
-8,713
| -21% | -$755K |
|
2689
PUT
Newell Brands
NWL
$2.62B
| $2.68M | ﹤0.01% |
720,000
-700,000
| -49% | -$2.83M |
|
2690
S&T Bancorp
STBA
$1.82B
| $2.68M | ﹤0.01% |
68,041
+12,397
| +22% | +$479K |
|
2691
Hillman Solutions
HLMN
$1.73B
| $2.68M | ﹤0.01% |
308,956
+29,910
| +11% | +$270K |
|
2692
Algonquin Power & Utilities
AQN
$4.44B
| $2.68M | ﹤0.01% |
435,026
-23,456
| -5% | -$139K |
|
|
BWIN
2693
Baldwin Insurance Group
BWIN
$3B
| $2.67M | ﹤0.01% |
111,314
+10,673
| +11% | +$272K |
|
|
CTO
2694
CTO Realty Growth
CTO
$819M
| $2.67M | ﹤0.01% |
145,291
+84,309
| +138% | +$1.44M |
|
2695
McEwen Inc
MUX
$1.18B
| $2.67M | ﹤0.01% |
+144,482
| New | +$2.69M |
|
2696
Amplitude
AMPL
$1.55B
| $2.67M | ﹤0.01% |
230,863
+85,735
| +59% | +$902K |
|
|
UMH
2697
UMH Properties
UMH
$1.39B
| $2.65M | ﹤0.01% |
166,624
+4,865
| +3% | +$73.1K |
|
2698
NeoGenomics
NEO
$2.11B
| $2.65M | ﹤0.01% |
225,178
-580,377
| -72% | -$6.26M |
|
2699
CALL
Philip Morris
PM
$290B
| $2.65M | ﹤0.01% |
16,500
+1,600
| +11% | +$248K |
|
2700
Scansource
SCSC
$1.06B
| $2.65M | ﹤0.01% |
67,728
+8,313
| +14% | +$343K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.